<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605993</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1210-PNH-201</org_study_id>
    <secondary_id>2015-002674-20</secondary_id>
    <nct_id>NCT02605993</nct_id>
  </id_info>
  <brief_title>Open-label, Multiple Ascending Dose Study of ALXN1210 in Patients With Paroxysmal Nocturnal Hemoglobinuria</brief_title>
  <official_title>A Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With PNH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of
      multiple IV doses of ALXN1210 administered to complement inhibitor treatment-naïve patients
      with PNH.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in lactate dehydrogenase (LDH) levels</measure>
    <time_frame>Baseline to Day 253 (Cohorts 1-3) or Day 281 (Cohort 4)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in free hemoglobin</measure>
    <time_frame>Baseline to Day 253 (Cohorts 1-3) or Day 281 (Cohort 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in haptoglobin</measure>
    <time_frame>Baseline to Day 253 (Cohorts 1-3) or Day 281 (Cohort 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in reticulocyte count</measure>
    <time_frame>Baseline to Day 253 (Cohorts 1-3) or Day 281 (Cohort 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PNH Red Blood Cell (RBC) Clone</measure>
    <time_frame>Baseline to Day 253 (Cohorts 1-3) or Day 281 (Cohort 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in D-dimer</measure>
    <time_frame>Baseline to Day 253 (Cohorts 1-3) or Day 281 (Cohort 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical manifestations of PNH</measure>
    <time_frame>Baseline to Day 253 (Cohorts 1-3) or Day 281 (Cohort 4)</time_frame>
    <description>Clinical manifestations are fatigue, abdominal pain, dyspnea, dysphagia, chest pain, and erectile dysfunction. Improvement defined as present at baseline and absent at Day endpoint. Worsening defined as absent at baseline and present at endpoint.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <condition>PNH</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALXN1210 1400 mg on Day 1, 1000 mg on Day 15 and Day 29 and every 4 weeks.
During the extension period, all patients switched to weight-based dosing as follows:
≥ 40 to &lt; 60 kg: 3000 mg every 8 weeks
≥ 60 to &lt; 100 kg: 3300 mg every 8 weeks
≥ 100 kg: 3600 mg every 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALXN1210 2000 mg on Day 1, 1600 mg on Day 22 and Day 43 and every 6 weeks.
During the extension period, all patients switched to weight-based dosing as follows:
≥ 40 to &lt; 60 kg: 3000 mg every 8 weeks
≥ 60 to &lt; 100 kg: 3300 mg every 8 weeks
≥ 100 kg: 3600 mg every 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALXN1210 1600 mg on Day 1 and Day 15, 2400 mg on Day 29 and every 8 weeks.
During the extension period, all patients switched to weight-based dosing as follows:
≥ 40 to &lt; 60 kg: 3000 mg every 8 weeks
≥ 60 to &lt; 100 kg: 3300 mg every 8 weeks
≥ 100 kg: 3600 mg every 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALXN1210 3000 mg on Day 1, 5400 mg on Day 29 and every 12 weeks.
During the extension period, all patients remained on the same dose regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALXN1210</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥ 18 years of age

          2. PNH diagnosis confirmed by documented high-sensitivity flow cytometry

          3. Documented meningococcal vaccination not more than 3 years prior to dosing

          4. Female patients of childbearing potential must use highly effective contraception
             starting at screening and continuing until at least 8 months after the last dose of
             ALXN1210.

          5. Willing and able to give written informed consent and comply with the study visit
             schedule

        Exclusion Criteria:

          1. Treatment with a complement inhibitor at any time

          2. Females who are pregnant, breastfeeding or who have a positive pregnancy test at
             screening or Day 1

          3. Participation in an interventional clinical study within 30 days before initiation of
             dosing on Day 1, or use of any experimental therapy within 30 days prior to dosing on
             Day 1, or within 5 half-lives of the investigational product, whichever is greater

          4. History of allergy to excipients of ALXN1210 or known allergy to Chinese hamster ovary
             (CHO) cell proteins

          5. Inability to comply with study requirements

          6. History of any clinically significant cardiac, hepatic, immunologic, pulmonary, or
             rheumatoid disease that, in the Investigator's judgment, would preclude participation

          7. Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make
             the patient unsuitable for enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Quebec</city>
        <zip>HIT 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Lyon</city>
        <state>Pierre-Bénite</state>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Ulm</city>
        <state>Baden Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Taipei City</city>
        <zip>1002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Airdrie</city>
        <state>North Lanarkshire</state>
        <zip>ML6 0JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <disposition_first_submitted>February 18, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>February 18, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 21, 2018</disposition_first_posted>
  <last_update_submitted>February 18, 2018</last_update_submitted>
  <last_update_submitted_qc>February 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>complement inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

